

## PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Professor Dr. Dr. Bernhard K. Keppler	07/30/2008
RECEIVING PARTY DATA	
Name:	Niiki Pharma Inc.
Street Address:	80 River Street, Suite 5D
City:	Hoboken
State/Country:	NEW JERSEY
Postal Code:	07030
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	5525598
CORRESPONDENCE DATA	
Fax Number:	(310)843-1274
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	(310)788-9900
Email:	riov@perkinscoie.com
Correspondent Name:	PERKINS COIE LLP
Address Line 1:	PATENT - LA
Address Line 2:	P.O. BOX 1208
Address Line 4:	SEATTLE, WASHINGTON 98111-1208
ATTORNEY DOCKET NUMBER:	63899.8005.US00
NAME OF SUBMITTER:	James J. Zhu, Reg. No. 52396
Total Attachments: 3 source=2008_09_17_15_46_05#page1.tif source=2008_09_17_15_46_05#page2.tif source=2008_09_17_15_46_05#page3.tif	

CH \$40.00 5525598

500650386

PATENT  
REEL: 021531 FRAME: 0937

## ASSIGNMENT

PROFESSOR DR. DR. BERNHARD K. KEPPLER, an individual at Dr. Baumgartnerstraße 18, 2191 Gaweinstal, Austria (hereinafter referred to as "ASSIGNOR") hereby assigns certain patent rights to Niiiki Pharma Inc., a Delaware corporation having its principal place of business at 80 River Street, Suite 5D, Hoboken, NJ 07030, U.S.A. (hereinafter referred to as "ASSIGNEE"):

WHEREAS, ASSIGNOR is the owner or co-owner or inventor of patent rights in the Letters Patents and Patent Applications set forth on APPENDIX A by assignment from Faustus Forschungs Cie. Translational Cancer Research GmbH or otherwise;

AND WHEREAS, ASSIGNOR is obligated to assign its patent rights to ASSIGNEE pursuant to a Patent Purchase Agreement between ASSIGNOR and ASSIGNEE (the "Agreement");

NOW, THEREFORE, in pursuance of the said Agreement ASSIGNOR, as beneficial owner or co-owner or inventor, hereby does sell, assign, transfer and set over, unto said ASSIGNEE, its successors, legal representatives and assigns, its right, title and interest in, to and under said Letters Patents and Patent Applications, as set forth in APPENDIX A, and all divisions, renewals, continuations and continuation-in-part thereof, and all Letters Patents of the United States which may be granted thereon and all reissues, reexaminations and extensions thereof, and all inventions disclosed, claimed, or embodied in said Letters Patents and Patent Applications, and all applications for Letters Patent filed for said inventions in any country or countries foreign to the United States, and all Letters Patents which may be granted for said inventions in any country or countries foreign to the United States and all extensions, renewals and reissues thereof and all rights of priority in any such country or countries based upon the filing of the said applications for Letters Patents of the United States which are created by any law, treaty or international convention, as set forth in APPENDIX A, and the full benefits thereof, and any rights, privileges and advantages appertaining thereto.

AND ASSIGNOR covenants that it has full right to convey the interest herein assigned, and that it has not executed, and will not execute, any agreement in conflict herewith.

AND ASSIGNOR HEREBY further covenants and agrees that it will communicate to said ASSIGNEE, its successors, legal representatives and assigns, any facts known to it respecting said inventions, and testify in any legal proceeding, sign all lawful papers, execute all divisional, continuing and reissue applications, make all rightful oaths and generally do everything possible to aid the said ASSIGNEE, its successors, legal representatives and assigns, to obtain and enforce proper patent protection for said invention in all countries.

IN TESTIMONY WHEREOF, ASSIGNOR hereunto sets its hand and seal the day and year set opposite its signature.

PROFESSOR DR. DR. BERNHARD K. KEPPLER



Date: July 30, 2008

Agreed and Accepted by:

NIKI PHARMA, INC.



By: Hooshmand Shesheberadaran, Ph.D.

Title: President and CEO

Date: July 30, 2008

## **APPENDIX A**

US Patent No. 5,525,598, entitled "Gallium (III) complexes in pharmaceutical compositions" issued from US Application No. 08/178,241 filed January 24, 1994.